As the maintenance UNIT, 200 PAU

Placebo arm of 1Arm A.

As the maintenance UNIT, 400 PAU

Placebo arm of 2Arm C.

As the maintenance UNIT, 800 PAU

Placebo arm of 3Arm E.

[Group 1] Group A receives 100 PAU at week 1 and 200 PAU at week 2 as the induction phase.

200 PAU is administered for 3 to 16 weeks as a maintenance phase.

Group B (placebo group) is the placebo arm of group A.

[Group 2] As the induction phase, group C received 100 PAU at week 1, 200 PAU at week 2, 300 PAU at week 3, and 400 PAU at week 4.

As the maintenance phase, 400 PAU is administered for 5 to 16 weeks.

Group D (placebo) is the placebo group in Group C.

[Group 3] As the induction phase, group E received 100 PAU at week 1, 200 PAU at week 2, 300 PAU at week 3, 400 PAU at week 4, 600 PAU at week 5, and 800 PAU at week 6.

As the maintenance phase, 800 PAU is administered from 7 to 16 weeks.

Group F (placebo) is the placebo arm of group E.

Blood pressure (mmHg), Heart rate (BPM), Body temperature(℃)

- Physical examination of necessary body parts by interviewing and observing the height (cm), weight (kg), auscultation (lung, heart), and other clinical test subjects

Hematologic examination

Blood coagulation test

Blood chemistry test

Measure the 12 lead electrocardiogram. All electrocardiograms are measured after the subject rests for at least 3 minutes in a supine position.

Local adverse events are removed from the subject 4 hours after attaching the clinical trial drug, and the attachment site is photographed and uploaded to the subject's diary (e-diary). The tester evaluates the presence of an adverse reaction through visual evaluation of the photo of the attachment site.